Page last updated: 2024-10-23

benserazide and Dizzyness

benserazide has been researched along with Dizzyness in 1 studies

Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.

Research Excerpts

ExcerptRelevanceReference
"Parkinsonian patients with orthostatic hypotension and dizziness due to usual antiparkinson therapy have been treated with the precursor amino-acid of noradrenaline, DL-3,4-threo-dihydroxyphenylserine (DL-3,4-threo-DOPS)."3.66DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness. ( Birkmayer, G; Birkmayer, W; Lechner, H; Riederer, P, 1983)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Birkmayer, W1
Birkmayer, G1
Lechner, H1
Riederer, P1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease[NCT01176240]Phase 3225 participants (Actual)Interventional2010-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ)

"The primary efficacy endpoint for 306A is the relative mean change in Orthostatic Hypotension Questionnaire (OHQ) composite score from baseline to end of study. The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.~For the change from baseline, negative numbers represent improvement from baseline in OHQ score." (NCT01176240)
Timeframe: Baseline, Week 8

Interventionunits on a scale (Mean)
Droxidopa-2.2
Placebo-2.1

306A Efficacy: Patient Reported Falls

The total number of patient reported falls during the 8 week treatment period (NCT01176240)
Timeframe: Baseline, Week 8

Interventiontotal falls per group (Number)
Droxidopa79
Placebo192

306B Efficacy: Change in Dizziness/Lightheadedness/Feeling Faint/Feeling Like You Might Black Out (OHSA Item 1)

OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 1 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline. (NCT01176240)
Timeframe: Baseline, Week1

Interventionunits on a scale (Mean)
Droxidopa-2.3
Placebo-1.3

306B Efficacy: Change in OHSA Item 1 From Baseline to Week 2 (Visit 5)

OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 2 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline. (NCT01176240)
Timeframe: Baseline, Week2

Interventionunits on a scale (Mean)
Droxidopa-1.9
Placebo-1.6

306B Efficacy: Change in OHSA Item 1 From Baseline to Week 4 (Visit 6)

OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 4 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline. (NCT01176240)
Timeframe: Baseline, Week4

Interventionunits on a scale (Mean)
Droxidopa-2.0
Placebo-1.5

306B Efficacy: Change in OHSA Item 1 From Baseline to Week 8 (Visit 7)

OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 8 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline. (NCT01176240)
Timeframe: Baseline, Week 8

Interventionunits on a scale (Mean)
Droxidopa-2.1
Placebo-1.5

306B Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ)

"The relative mean change in Orthostatic Hypotension Questionnaire (OHQ) composite score from baseline to end of study. The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.~For the change from baseline, negative numbers represent improvement from baseline in OHQ score." (NCT01176240)
Timeframe: Baseline, Week 8

Interventionunits on a scale (Mean)
Droxidopa-2.2
Placebo-2.0

306B Efficacy: Change in Systolic Blood Pressure (SBP) Measurements Post Standing From Baseline to Week 1

Measure: Lowest standing systolic blood pressure reading of immediately post standing and 3 minutes post standing. Change: standing systolic blood pressure at Week 1 (Visit 4) minus standing systolic blood pressure at baseline. A positive score indicates an improvement in standing systolic blood pressure during the double-blind randomized phase relative to value at baseline. (NCT01176240)
Timeframe: Baseline, Week 1

InterventionmmHg (Mean)
Droxidopa6.4
Placebo0.7

306B Efficacy: Rate of Patient Reported Falls

The average number of patient reported falls per week. (NCT01176240)
Timeframe: up to 10 weeks

Interventionfalls per week (Mean)
Droxidopa0.4
Placebo2.0

Study 306A: Change in Dizziness/Lightheadedness/Feeling Faint/Feeling Like You Might Black Out (OHSA Item 1) From Baseline to Week 1

OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 1 minus score at baseline. A negative score indicates improvement in symptoms during the double-blind randomized phase relative to value at baseline. (NCT01176240)
Timeframe: Baseline, Week 1

Interventionunits on a scale (Mean)
Droxidopa-3.1
Placebo-1.6

Other Studies

1 other study available for benserazide and Dizzyness

ArticleYear
DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
    Journal of neural transmission, 1983, Volume: 58, Issue:3-4

    Topics: Aged; Antiparkinson Agents; Benserazide; Blood Pressure; Dizziness; Droxidopa; Drug Therapy, Combina

1983